

Lung Yi Mak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3480569/lung-yi-mak-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75 papers	991 citations	18 h-index	29 g-index
118 ext. papers	1,586 ext. citations	5.7 avg, IF	4.85 L-index

#	Paper	IF	Citations
75	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , 2022 , 56, e31-e37	3	0
74	RNA interference as a novel treatment strategy for chronic hepatitis B infection.. <i>Clinical and Molecular Hepatology</i> , 2022 ,	6.9	6
73	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction.. <i>Frontiers in Microbiology</i> , 2022 , 13, 813783	5.7	0
72	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma.. <i>Hepatology International</i> , 2022 , 1	8.8	0
71	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	
70	Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: A self-controlled case series study.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	2
69	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , 2021 , 73, 2167-2179	11.2	17
68	Patient plgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
67	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2021 , 16, 48	8.8	2
66	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2021 ,	19.2	7
65	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2021 , 21, 123	3	3
64	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021 , 7, 88	6.9	5
63	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. <i>Hepatology International</i> , 2021 , 15, 881-891	8.8	0
62	Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. <i>Viruses</i> , 2021 , 13,	6.2	5
61	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021 , 15, 901-911	8.8	1
60	REPLY. <i>Hepatology</i> , 2021 , 74, 533-534	11.2	
59	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1315-1326	4	5

58	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , 2021 , 70, 775-783	19.2	18
57	Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies. <i>Liver Transplantation</i> , 2021 , 27, 134-139	4.5	1
56	New insights on missed colonic lesions during colonoscopy through artificial intelligence-assisted real-time detection (with video). <i>Gastrointestinal Endoscopy</i> , 2021 , 93, 193-200.e1	5.2	14
55	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021 , 56, 479-488	6.9	6
54	Novel Therapy for Functional Cure of Chronic Hepatitis B Virus Infection 2021 , 455-473		
53	Detection of the hepatitis B surface antigen in patients with occult hepatitis B using an assay with enhanced sensitivity.. <i>Journal of Clinical Microbiology</i> , 2021 , jcm0220421	9.7	0
52	Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. <i>Journal of Hepatology</i> , 2020 , 73, 952-964	13.4	41
51	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 800-806	13.4	19
50	Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00138	4.2	9
49	Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020 , 19, 293-301	1	3
48	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 420-421	18.8	
47	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020 , 9,	3.6	21
46	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020 , 14, 665-668	4.8	2
45	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020 , 72, 818-828	11.2	5
44	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 397-406	3.4	8
43	Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <i>Hepatology International</i> , 2020 , 14, 35-46	8.8	14
42	Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , 2020 , 73, 1573-1574	13.4	17
41	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00236	4.2	9

40	Nidogen 1-Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. <i>Advanced Science</i> , 2020 , 7, 2002157	13.6	18
39	Linked color imaging versus narrow-band imaging for colorectal polyp detection: a prospective randomized tandem colonoscopy study. <i>Gastrointestinal Endoscopy</i> , 2020 , 91, 104-112.e5	5.2	12
38	DOP64 Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S067-S068	1.5	
37	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1924-1933	7	17
36	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019 , 13, 148-156	8.8	8
35	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019 , 220, 940-950	7	2
34	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 818-827	3.4	19
33	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , 2019 , 39, 1217-1225	7.9	5
32	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019 , 19, 789	4.8	7
31	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1473-1480	3.4	7
30	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3630-3641	4	
29	Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. <i>Current Hepatology Reports</i> , 2019 , 18, 503-511	1	5
28	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1398-1408	5.6	9
27	New Biomarkers of Chronic Hepatitis B. <i>Gut and Liver</i> , 2019 , 13, 589-595	4.8	23
26	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1817-1823	4	9
25	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 109-120	3.8	20
24	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1410-1412	6.9	7
23	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 101-106	5.5	2

22	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 483-491	5.5	4
21	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. <i>Hepatology</i> , 2018 , 68, 462-472	11.2	39
20	Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 141-149	4	10
19	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 575-583.e2	6.9	46
18	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 43-54	6.1	105
17	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study. <i>Journal of Hepatology</i> , 2018 , 68, S478	13.4	3
16	Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1720-1721	6.1	0
15	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 97-104	3.4	42
14	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 262-279	7.1	99
13	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 163	4.2	18
12	The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017 , 37, 1287-1294	7.9	4
11	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 1153-1159	15.9	23
10	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e125	4.2	64
9	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017 , 8, 47507-47517	7.3	23
8	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7716-7726	5.6	21
7	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7863-7874	5.6	7
6	Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis. <i>Journal of Digestive Diseases</i> , 2016 , 17, 610-617	3.3	6
5	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 383-92	4.1	18

- 4 Gallstone Ileus in an Older Nursing Home Resident. *Journal of the American Geriatrics Society*, **2016**, 64, 447-9 5.6 1
- 3 Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 1071-1079 6.1 19
- 2 A case of platypnea-orthodeoxia syndrome in an elderly lady. *European Geriatric Medicine*, **2015**, 6, 467-468 5
- 1 Attitudes and perceptions of influenza vaccination among Hong Kong doctors and medical students before the 2009 pandemic. *European Journal of Public Health*, **2013**, 23, 257-62 2.1 9